Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset

Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.

Choosing the key to success from hanging keys concept for aspirations, achievement and incentive
Roche hopes Tusk holds the Treg depletion key • Source: Shutterstock

A little-known company based in the Stevenage Bioscience Catalyst between London and Cambridge, UK, has been acquired by Roche for €70m plus up to €585m in milestone payments. Roche says it may use Tusk Therapeutics’ asset in combination with its approved checkpoint inhibitor Tecentriq (atezolizumab), and could evaluate other combinations in the future.

Roche bought the company for its anti-CD25 antibody, which is designed to target regulatory T-cells (Tregs) in the tumor micro-environment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

What To Look Out For At ESMO 2024

 

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Anticancer

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Ordspono Will Be Regeneron’s First Independent European Launch

 

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.